DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,906,140 B2 Bromley Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,906,140 B2 Bromley Et Al USOO79061.40B2 (12) United States Patent (10) Patent No.: US 7,906,140 B2 Bromley et al. (45) Date of Patent: Mar. 15, 2011 (54) COMPOSITIONS FOR MUCOSAL DELIVERY 5,178,878 A 1/1993 Wehling et al................ 424/466 OFAGENTS 5, 182,107 A 1/1993 Friden ........................ 424,85.91 5,234,957 A 8, 1993 Mantelle et al. O O 5,298,246 A 3, 1994 Yano et al. (75) Inventors: Philip James Bromley, Fullerton, CA 5,323,907 A 6/1994 Kalvelage ..................... 206,531 (US); Lee Nickols Huang, Diamond 5,527,527 A 6/1996 Friden ............ 424,178.1 Bar, CA (US) 5,620,708 A 4/1997 Amkraut et al. .............. 424/491 s 5,672,683 A 9, 1997 Friden et al. ....... 530/350 5,702,727 A 12/1997 Amkraut et al. ... ... 424/491 (73) Assignee: Virun, Inc., City of Industry, CA (US) 5,744,155. A 4, 1998 Friedman et al. ............. 424/434 5,833,988 A 11/1998 Friden ................ 424,178.1 (*) Notice: Subject to any disclaimer, the term of this 5,977,307. A 1 1/1999 Friden et al. ... 530/350 patent is extended or adjusted under 35 2. A 1 &28 Esta s al 25: U.S.C. 154(b) by 1526 days. 6,329,508W . B1 12/2001 FridenayWard ............ et al. ... 530,387.3 6,383,513 B1* 5/2002 Watts et al. ................... 424/450 (21) Appl. No.: 11/155,262 (Continued) (22) Filed: Jun. 16, 2005 FOREIGN PATENT DOCUMENTS (65) Prior Publication Data CA 2229286 A1 8, 1999 US 2005/028.1772A1 Dec. 22, 2005 (Continued) OTHER PUBLICATIONS Related U.S. Application Data (60) Provisional application No. 60/580,877, filed on Jun. HandBook of Pharmaceutical Excipients, 1986 Ed. Lecithin, p. 165.* 17, 2004. (Continued) (51) Int. Cl. Primary Examiner — Robert A Wax A6 IK38/00 (2006.01) Assistant Examiner — Melissa S. Mercier (52) U.S. Cl. ................................. 424/450; 514/2: 514/8 (74) Attorney, Agent, or Firm — K&L Gates LLP; Stephanie (58) Field of Classification Search ........................ None Seidman See application file for complete search history. (57) ABSTRACT (56) References Cited Compositions and methods for mucosal delivery of agents are provided. The compositions are intended for administration U.S. PATENT DOCUMENTS to mucosal Surface. Such as oral and nasal mucosa. The com 4,740,365 A 4, 1988 Yukimatsu et al. ........... 424/435 positions provided contain one or more mucoadhesive pro 4,889,720 A 12, 1989 Konishi ........................ 25 teins and an agent to be delivered. Methods for delivery of 4,900,552 A * 2/1990 Sanvordeker et al. ........ 424/422 agent ing th iti ided herei 1 4,921,706 A 5/1990 Roberts et al. ................ 424/450 gen SuS1ng une compos1u1ons prov1de erein are also pro 5,033,252 A 7/1991 Carter .......... .534/25 vided. 5,052,558 A 10/1991 Carter ........................... 206,439 5,154,924 A 10, 1992 Friden ........................ 424,179.1 50 Claims, 1 Drawing Sheet Oral insulin-Human Glucose Levels OO O Time (hrs) US 7,906.140 B2 Page 2 U.S. PATENT DOCUMENTS Lehr, et al., “Visualization studies of the mucoadhesive interface.” 6,426,362 B1* 7/2002 Miller et al. .................. 514,458 Journal of Controlled Release, 18:249-260 (1992). 6,475,511 B2 11/2002 Gohlke et al. ................ 424/441 Nogrady, Medicinal Chemistry A Biochemical Approach, New York: 6,552,024 B1 4/2003 Chen et al. Oxford University Press, pp. 388-392 (1985). 6,638,521 B2 10/2003 Dobrozsi et al. .............. 424/434 Peppas & Buri, "Surface, Interfacial and Molecular Aspects of Poly 6,749,863 B1 6/2004 Chang et al. ... 424/450 mer Bioadhesion on soft tissues.” Journal of Controlled Release, 6,905,688 B2 6, 2005 Rosen et al. 424,192.1 6,926,898 B2 8, 2005 Rosen et al. 424,192.1 2:257-275 (1985). 6,946,134 B1 9, 2005 Rosen et al. 424,192.1 Ryan et al. “Immunomodulators and delivery systems for vaccination 6,994,857 B2 2/2006 Rosen et al. 424,192.1 by mucosal routes' Trends in Biotechnology, vol. 19, No. 8, pp. 7,179,484 B2 * 2/2007 Singh .......... 424/450 293-304. (2001). 2003/0171267 A1 9, 2003 Rosen et al. ... 514/12 Simoes et al., “Mechanisms of gene transfer mediated by lipoplexes 2003/0219472 A1 11, 2003 Pauletti et al. 424/449 associated with targeting ligands or pH-sensitive peptides' Gene 2003/0221201 A1 11/2003 Prior et al. ........................ 800.7 Ther. (11): 1798-807 (1999). 2003/0226155 Al 12/2003 Sadeghi et al. ................... 800.7 2004/0010134 A1 1/2004 Rosen et al. 536,235 Smart et al., “An in-vitro investigation of mucosa-adhesive materials 2004/OO23334 A1 2/2004 Prior ........... 435/69.7 for use in controlled drug delivery,” J. Pharm. Pharmacol. 36:295. 2004/0037809 A1 2/2004 Quay et al. 424,856 (1984). 2004/OO77540 A1 4/2004 Quay .......... ... 514/12 Smart et al., “In vitro techiniques for measuring mucoadhesion.” J. 2005, 0196440 A1* 9, 2005 Masters et al. 424/464 Pharm. Pharmacol. 34:70P (1982). 2005/O197495 A1 9, 2005 Naidu ......... 530/400 Tabor et al., "Surface forces and surface interactions' Journal of 2006, OO84794 A1 4/2006 Rosen et al. ... 530,363 Colloid and Interface Science, vol. 58, Issue 1. pp. 2-13 (1977). 2006/0093594 A1 5/2006 Naidu ........................ 424/9345 Oratropin-1TM Website Printout, foundat: www.ibe-technology.com/ oratropin.htm retrieved on Jan. 20, 2006 6 pages). FOREIGN PATENT DOCUMENTS Ectotropin-6TM Website Printout, found at: www.ibe-technology. WO 2006/00982.5 1, 2006 com/ectotropin.htm retrieved on Jan. 20, 20064 pages. WO WO 2009,11715.1 9, 2009 HexaTropin-6TM Website Printout, found at: www.ibe-technology. WO WO 2009,117152 9, 2009 com/hexatropin.htm retrieved on Jan. 20, 20063 pages). U.S. Appl. No. 60/527,962, filed Dec. 8, 2003, Masters et al. OTHER PUBLICATIONS Virun Improving Life Through Safe & Effective Oral Delivery found Almeida et al. "Nasal Delivery of Vaccines,” Journal of Drug Target at: www.slideshare.net/virun?virun-improving-life-through-safe-ef ing 3, 456-467 (1996). fective-oral-delivery accessed on May 11, 2009). Ansel, Introduction to Pharmaceutical Dosage Forms, Fourth Edi Wright, R., “Companies to watch Nutraceuticals World,” at: www. tion, Philadelphia: Lea& Febiger, p. 126 (1985). nutraceuticalsworld.com/articles/2009/06/companies-to-watch, Budavari, et al.(Eds.) The Merck Index, 12th Edition, Whitehouse (2009) accessed on Jun. 4, 2009). Station, N.J.Merck & Co., pp. THER-1 to THER-28 (1996). U.S. Appl. No. 12/383,244, filed Mar. 20, 2009. Drug Delivery Technology, Alkaline Acidic Triggering Effect pam U.S. Appl. No. 12/383.241, filed Mar. 20, 2009. phlet.2 pages, Archimedes Laboratories, Inc., Sep. 2005. U.S. Appl. No. 12/456,926, filed Jun. 23, 2009. Drug Delivery Technology, Pre-Clinical Abstract, Oral U.S. Appl. No. 12/583,209, filed Aug. 13, 2009. Pharmacokinetics of MAPED (Mucosa Adhesive Protein Engineered An English language translation of a Chinese Examination Report, Drugs) Bound in Human Recombinant Insulin, 6 pages, Archimedes issued Mar. 1, 2010, in connection with corresponding Chinese Laboratories, Inc., Sep. 2005. Patent Application No. 200580028061.8. Drug Delivery Technology, Undenatured Protein pamphlet, 2 pages, Examination Report, issued Jul. 21, 2008, in connection with Euro Archimedes Laboratories, Inc., Sep. 2005. pean Patent Application No. 05762240.9. Good, Surface free energy of Solids and liquids: Thermodynamics, Office Action, issued Nov. 26, 2008, in connection with Chinese molecular forces, and structure Journal of Colloid and Interface Sci Patent Application No. 200580028061.8. ence, vol. 59, Issue 3, pp. 398-419 (1977). Examination Report, issued Dec. 3, 2008, in connection with Cana Gu, et al. “Binding of Acrylic Polymers to Mucin/Epithelial Sur dian Patent Application No. 2.578,709. faces: Structure-Property Relationships.” Critical Reviews in Thera peutic Drug Carrier Systems 5(1): 21-67 (1988). * cited by examiner U.S. Patent Mar. 15, 2011 US 7,906,140 B2 Figure 1 Oral insulin - Human Glucose Levels O a. s E Ye O (9 P CD US 7,906,140 B2 1. 2 COMPOSITIONS FOR MIUCOSAL DELVERY istration of agents to animals, including humans. Provided are OFAGENTS compositions and methods for administering Substances to animals, including humans, employing a carrier that facili RELATED APPLICATIONS tates entry of the Substance to the mucosa in a non-specific 5 a. This application claims priority under 35 U.S.C. S 119(e) to The compositions provided herein are stable emulsions of U.S. provisional application Ser. No. 60/580,877, entitled oil in water or water in oil, wherein an agent to be delivered is COMPOSITIONS FOR MUCOSAL DELIVERY OF dissolved in either the oil phase or the water phase. The AGENTS’ to Bromley et al. filed Jun. 17, 2004. The subject emulsions are typically stabilized by Surface active molecules matter of the provisional application is incorporated by ref 10 in the emulsion. The surfactant molecules form various erence herein. This application is related to International PCT application macro-molecular structures in an emulsion, such as micelles, No PCT/US05/21424 filed on the same day herewith. The inverse micelles, lipid bilayers (liposomes) and cubosomes. subject matter of the PCT application is incorporated by The exact macromolecular structure formed depends on the reference herein. relative sizes of the hydrophilic and hydrophobic regions of 15 the surface active molecule. The agent to be delivered can be FIELD distributed between the hydrophobic and hydrophilic phases of an oil in water or water in oil type emulsion, or can be Provided herein are pharmaceutical compositions for present predominantly in one of the phases.
Load more

Recommended publications
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • A Thesis Submitted for the Degree of Doctor of Philosophy in The
    A thesis submitted for the Degree of Doctor of Philosophy in the University of London METABOLIC AND DISPOSITION STUDIES Oy QUATERNARY AMMONIUM COMPOUNDS IN MAN AND LABORATORY SPECIES by JOSEPH D'SOUZA, B.Sc. Department of Biochemical and Experimental Pharmacology, St Mary's Hospital Medical School, London W2 1PG December 1979 -2- To My Parents with Love & Gratitude -3- ABSTRACT The work described in this thesis deals with two aspects of the biochemical pharmacology of quaternary ammonium compounds. The first part deals with the disposition of a quaternary ammonium neuromuscular blocking drug, fazadinium bromide. A convenient radiometric assay for this drug in biological fluids was developed, and applied to the study of its disposition in patients with normal and impaired renal function. The second part describes a study of the metabolic N- methylation and hence quaternisation, of 14C -pyridine in vivo. The main findings are as follows: - A) Disposition studies in the dog and man showed that biliary excretion is an important pathway for the elimination of fazadinium. i) The ratio of the hepatic to renal excretion being 3:1 in the dog, whilst in man, faecal elimination arising presumably from biliary excretion accounted for over one-third the total elimination. ii) Biliary excretion was not augmented to compensate for renal dysfunction after bilateral renal pedicle ligation in the dog; metabolic studies showed the major metabolite in the urine and bile of dogs was 3-methyl-2-phenylimidazole (1,2a) pyridinium, but an "unknown" metabolite in human urine was also detected. B) Clinical studies demonstrated no significant alterations in the pharmacokinetic or pharmacodynamic properties of fazadinium in patients with normal or impaired renal function.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Pharmacology on Your Palms CLASSIFICATION of the DRUGS
    Pharmacology on your palms CLASSIFICATION OF THE DRUGS DRUGS FROM DRUGS AFFECTING THE ORGANS CHEMOTHERAPEUTIC DIFFERENT DRUGS AFFECTING THE NERVOUS SYSTEM AND TISSUES DRUGS PHARMACOLOGICAL GROUPS Drugs affecting peripheral Antitumor drugs Drugs affecting the cardiovascular Antimicrobial, antiviral, Drugs affecting the nervous system Antiallergic drugs system antiparasitic drugs central nervous system Drugs affecting the sensory Antidotes nerve endings Cardiac glycosides Antibiotics CNS DEPRESSANTS (AFFECTING THE Antihypertensive drugs Sulfonamides Analgesics (opioid, AFFERENT INNERVATION) Antianginal drugs Antituberculous drugs analgesics-antipyretics, Antiarrhythmic drugs Antihelminthic drugs NSAIDs) Local anaesthetics Antihyperlipidemic drugs Antifungal drugs Sedative and hypnotic Coating drugs Spasmolytics Antiviral drugs drugs Adsorbents Drugs affecting the excretory system Antimalarial drugs Tranquilizers Astringents Diuretics Antisyphilitic drugs Neuroleptics Expectorants Drugs affecting the hemopoietic system Antiseptics Anticonvulsants Irritant drugs Drugs affecting blood coagulation Disinfectants Antiparkinsonian drugs Drugs affecting peripheral Drugs affecting erythro- and leukopoiesis General anaesthetics neurotransmitter processes Drugs affecting the digestive system CNS STIMULANTS (AFFECTING THE Anorectic drugs Psychomotor stimulants EFFERENT PART OF THE Bitter stuffs. Drugs for replacement therapy Analeptics NERVOUS SYSTEM) Antiacid drugs Antidepressants Direct-acting-cholinomimetics Antiulcer drugs Nootropics (Cognitive
    [Show full text]
  • Food and Drug Administration, HHS § 310.201
    Food and Drug Administration, HHS § 310.201 (d) Prescription legend not allowed on (v) The preparation is labeled with exempted drugs. The use of the prescrip- adequate directions for use in minor tion caution statement quoted in sec- conditions as a simple analgesic. tion 503(b) (4) of the act, in the labeling (vi) The dosages of N-acetyl-p-amino- of a drug exempted under the provi- phenol recommended or suggested in sions of this section, constitutes mis- the labeling do not exceed: For adults, branding. Any other statement or sug- 0.65 gram (10 grains) per dose or 2.6 gestion in the labeling of a drug ex- grams (40 grains) per 24-hour period: for empted under this section, that such children 6 to 12 years of age, one-half of drug is limited to prescription use, the maximum adult dose or dosage; for may constitute misbranding. children 3 to 6 years of age, one-fifth of (e) Prescription-exemption procedure of the maximum adult dose or dosage. OTC drug review. A drug limited to pre- (vii) The labeling bears, in juxtaposi- scription use under section 503(b)(1)(B) tion with the dosage recommendations, of the act may also be exempted from a clear warning statement against ad- prescription-dispensing requirements ministration of the drug to children by the procedure set forth in § 330.13 of under 3 years of age and against use of this chapter. the drug for more than 10 days, unless such uses are directed by a physician. [39 FR 11680, Mar.
    [Show full text]
  • Tractatenblad
    32 (1960) Nr. 1 TRACTATENBLAD VAN HET KONINKRIJK DER NEDERLANDEN JAARGANG 1960 Nr. 143 Verbeterblad A. TITEL Vijfde Aanvullend Protocol bij het op 25 juli 1958 te Brussel ondertekende Protocol tussen het Koninkrijk der Nederlanden, het Koninkrijk België en het Groothertogdom Luxemburg tot vaststelling van een nieuw tarief van invoerrechten, met Bijlage; Brussel, 1 december 1960 B. TEKST In de tekst dienen de volgende verbeteringen te worden aange- bracht: Blz. 61, post 22.04, kolom „Tarief E.G.": „2205" te lezen: 22.05; Blz. 61, post 22.05-B-II-6, kolom „Tarief Algemeen" en kolom „Tarief E.G.": „vrij 1)" te lezen: vrij 2); Blz. 61, noot 1): „dan 12 graden", te lezen: dan 12 graden, doch niet meer dan 13 graden; Blz. 61 (onderaan), op te nemen noot 2), luidende: 2) Zie noot x) op bladzijde 62; Blz. 98, post 29.08-A-IH-d-2: „dieen estrol" te lezen: dieeneströl; Blz. 220, post 69.11-B, kolom „Tarief E.G.": „of naar" te lezen: of, naar. 32 (1960) Nr. 1 TRACTATENBLAD VAN HET KONINKRIJK DER NEDERLANDEN JAARGANG 1960 Nr. 143 A. TITEL Vijfde Aanvullend Protocol bij het op 25 juli 1958 te Brussel ondertekende Protocol tussen het Koninkrijk der Nederlanden, het Koninkrijk België en het Groothertogdom Luxemburg tot vaststelling van een nieuw tarief van invoerrechten, met Bijlage; Brussel, 1 december 1960 B. TEKST x) Vijfde Aanvullend Protocol bij het op 25 juli 1958 te Brussel ondertekende Protocol tussen België, Luxemburg en Nederland tot vaststelling van een nieuw tarief van invoerrechten De Regeringen van het Koninkrijk België, het Groothertogdom
    [Show full text]
  • Author Index Page Numbers in Italics Refer to Bibliography
    Author Index Page Numbers in italics refer to bibliography Aaron,T.H., Criep,L.H. 180. Adams,M.R., see Litchfield,J. Albert,A., Serjeant,E.P. 176, 207 T., Jr. 386, 409, 432, 441, 207 Aaron, T. H., see Criep, L. H. 465,496 Albert,J.R., see Lish,P.M. 398,427 Adamson,D.W., Barrett,P.A., 449, 465, 466, 495 Aarsen,P.N., Zeegers,A. 15, Billinghurst, J. W., Green, A. Albert, U., see Giertz, H. 444, 30 F .. Jones,T.S.G. 190,192, 489 Abbozzo, G., Genazzani, E., 207 Alberty,J. 387,425, 442, Donatelli, L. 562,570 Adamson, D. W., Barrett, P. A., 452--455,480 Abdel-Galil, A. A. M., Marshall, Billinghurst,J. W., Jones, T. Alberty, J., Huurrekorpi, L. P. B. 114, 122 S.G. 190,207 399, 425, 455, 480 Aborg, e.-H .. Novotny,J., Adamson, D. W., Billinghurst, Alberty,J., Schiede,M. 399, Uvniis,B. 86.90 J.W. 189,194,207 425,455,480 Aborg,e. H., Uvniis,B. 87, 90 Adashek, D., Grossman, M. I. Alberty, J., Takkunen, R. 467, Aborg, C.-H., see Uvniis,B. 58. 46,47,55 480 74. 75, 82, 84-87. 92 Adlerova, E., see Protiva, M. Albinus,M., Sewing.K.F. 2, Abram, L. E., see Cohen, M. B. 201, 212 3, 6, 8, 11, 21, 30, 264, 287, 421,427 Ado,A.D., Abrossimow,W.N. 463,480 Abrams,G., see Lear,E. 566, 453.480 Albrecht, I., see Cort, J. H. 579, 571 Ado, A. D., Ishimova, L. M., 597 Abramson, D.
    [Show full text]